An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder

Wilens, Timothy E.; Prince, Jefferson B.; Spencer, Thomas; Patten, Stephanie L. Van; Doyle, Robert; Girard, Kristine; Hammerness, Paul; Goldman, Sarah; Brown, Sarah; Biederman, Joseph

doi:10.1016/s0006-3223(02)01664-5

Cited by 71 publications

(27 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, previous studies show that adults with ADHD are acceptable reporters of their own conditions even for their childhood, and selfreport of ADHD symptoms is a reliable and valid method of assessing ADHD in adults. 22,23 In conclusion, despite the growing number of studies indicating high comorbidity of ADHD and BD including the present one, the nature of the comorbidity between ADHD and BD has not as yet been clearly defined. The phenomenological overlap between these two disorders, and changes in the courses of these disorders over time should always be considered in the diagnosis of each disorder at all ages.…”

Section: Discussionmentioning

confidence: 72%

Adult attention‐deficit hyperactivity disorder in patients with bipolar I disorder in remission: Preliminary study

Tamam

Tuğlu

Karataş

et al. 2006

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Attention-deficit hyperactivity disorder (ADHD), a syndrome that typically first appears in early childhood, can occur in individuals of all ages. Prospective studies have demonstrated that at least half of children diagnosed as having ADHD continue to suffer the symptoms of this disorder in their adult life with significant impacts on their social status, achievement level and sense of wellbeing. The purpose of this preliminary study was to determine the rate of ADHD in patients with bipolar disorder (BD) and to examine the effects of comorbid ADHD on several clinical and sociodemographic variables of bipolar patients. Forty-four BD-I patients followed up in psychiatric outpatient clinics in two university hospitals, were assessed for the presence of adult ADHD according to DSM-IV. All patients also completed the Wender Utah Rating Scale for objective evaluation of ADHD. Of 44 patients with BD-I, only seven (15.9%) fulfilled criteria for a diagnosis of adult ADHD. Bipolar disorder-I patients with comorbid ADHD were more likely to be female, and have more affective episodes (especially depressive episodes) than bipolar patients without comorbid ADHD. Age at onset of affective illness was not significantly different between the two groups. In line with results of several previous reports, the present study also showed higher prevalence of ADHD in patients with BD-I than in normal population. A higher number of affective episode in patients with comorbid ADHD may suggest a more severe clinical course of BD in these patients. A larger group of samples is required to clarify the exact association and interaction between these two clinical entities.

show abstract

Section: Discussionmentioning

confidence: 72%

Adult attention‐deficit hyperactivity disorder in patients with bipolar I disorder in remission: Preliminary study

Tamam

Tuğlu

Karataş

et al. 2006

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…Recommendations were to treat bipolar symptoms first with mood stabilizers and/or atypical antipsychotics to stabilize mood before considering treatment for ADHD symptoms. Mixed amphetamine salts (level 3),611 methylphenidate (level 3),612 atomoxetine (level 4),615 bupropion (level 4),766 or lisdexamfetamine (level 4)767 add‐ons to mood‐stabilizing treatments have been reported to be efficacious in improving ADHD symptoms.…”

Section: Specific Populationsmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

“…Bupropion is very useful for treating of patients with bipolar disorder because bupropion-treated patients appeared less likely to switch to mania (Wilens et al 2003;Fava et al 2005).…”

Section: Treatment Of Adult Adhd Bupropionmentioning

confidence: 99%

Treatment of adults with attention-deficit/hyperactivity disorder

Kolář

Keller²,

Golfinopoulos³

et al. 2008

NDT

View full text Add to dashboard Cite

This review focuses on the treatment of attention defi cit hyperactivity disorder (ADHD) in adults. It briefl y addresses prevalence, diagnostic and differential diagnostic issues specifi c to adults. Stimulant medication, non-stimulant medication, and psychosocial treatments are thoroughly reviewed. For each class of medication possible mechanism of action, effi cacy and side effects are summarized. Special attention is given to the pharmacological treatment for patients with adult ADHD and various comorbidities. In summary, stimulant medications are most effective and combined medication and psychosocial treatment is the most benefi cial treatment option for most adult patients with ADHD.

show abstract

An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder

Cited by 71 publications

References 42 publications

Adult attention‐deficit hyperactivity disorder in patients with bipolar I disorder in remission: Preliminary study

Adult attention‐deficit hyperactivity disorder in patients with bipolar I disorder in remission: Preliminary study

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Treatment of adults with attention-deficit/hyperactivity disorder

Contact Info

Product

Resources

About